We have a tiny, little-known drug maker here in my town. The name of the company wouldn't ring a bell to anyone. I know a big pharma asks that little batches of one niche drug are made as needed. Not cost efective for biggie to make it themselves. It's all very descrete and confidential. 'Could be how Kevetrin or Prurisol is handled eventually -- or not. Only one of many ways medicines get to market.
It seems Prurisol has dropped out of the mix here. My guess is that it is something more than manufacturing efficiency that is causing the delay. That said, I have no firm evidence of anything at all. I am simply speculating based on experience with other companies over several decades. It could be simply that there isn't time for it.
I think CTIX should hire another person or two to champion Prurisol.
Many of the announced supplemental actions on Kevetrin seem to be on hold pending results of Phase 1. That is as it should be, in my opinion. It seems reasonable to want at least a safety profile before starting combination studies or going after different cancers.
Market Data 
Markets 
AI
